Investigational Drug Information for INCB054707

What is the development status for investigational drug INCB054707?

INCB054707 is an investigational drug.

There have been 13 clinical trials for INCB054707. The most recent clinical trial was a Phase 2 trial, which was initiated on November 27^th 2023.

The most common disease conditions in clinical trials are Hidradenitis Suppurativa, Hidradenitis, and Kidney Diseases. The leading clinical trial sponsors are Incyte Corporation, Incyte Biosciences Japan GK, and [disabled in preview].

There are fifty-three US patents protecting this investigational drug and two hundred and thirteen international patents.

Summary for INCB054707

US Patents	53
International Patents	213
US Patent Applications	141
WIPO Patent Applications	41
Japanese Patent Applications	5
Clinical Trial Progress	Phase 2 (2023-11-27)
Vendors	21

Recent Clinical Trials for INCB054707

Title	Sponsor	Phase
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V1)	Incyte Corporation	Phase 3
A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2)	Incyte Corporation	Phase 3
A Study to Evaluate the Pharmacokinetics and Safety of INCB054707 in Participants With Normal Hepatic Function and Participants With Hepatic Impairment	Incyte Corporation	Phase 1

See all INCB054707 clinical trials

Clinical Trial Summary for INCB054707

Top disease conditions for INCB054707

Top clinical trial sponsors for INCB054707

See all INCB054707 clinical trials

US Patents for INCB054707

Drugname	Patent Number	Patent Title	Patent Assignee	Estimated Expiration
INCB054707		Bicyclic fused pyrimidine compounds as TAM inhibitors	Incyte Corporation (Wilmington, DE)
INCB054707		Pyrrolopyrimidine derivatives as TAM inhibitors	Incyte Corporation (Wilmington, DE)
INCB054707		Treatment of B-cell malignancies by a combination JAK and PI3K inhibitors	Incyte Corporation (Wilmington, DE)
INCB054707		Heterocyclic compounds as PI3K-.gamma. inhibitors	Incyte Corporation (Wilmington, DE)
INCB054707		Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors	Incyte Corporation (Wilmington, DE)
INCB054707		Crystalline forms of a PI3K inhibitor	Incyte Corporation (Wilmington, DE)
INCB054707		Salts and processes of preparing a PI3K inhibitor	Incyte Corporation (Wilmington, DE)

International Patents for INCB054707

Drugname	Country	Document Number	Estimated Expiration	Related US Patent
INCB054707	World Intellectual Property Organization (WIPO)	WO2017027717	2035-08-12
INCB054707	World Intellectual Property Organization (WIPO)	WO2017035366	2035-08-26
INCB054707	Australia	AU2015244044	2034-04-08
INCB054707	Australia	AU2020213313	2034-04-08
INCB054707	Australia	AU2022206693	2034-04-08
INCB054707	Brazil	BR112016023322	2034-04-08
INCB054707	Brazil	BR122021024771	2034-04-08

INCB054707 Development Update and Market Projection

Last updated: February 28, 2026

What is INCB054707 and its current development status?

INCB054707 is a selective TYK2 (tyrosine kinase 2) inhibitor developed by Incyte Corporation. It targets cytokine signaling pathways involved in autoimmune diseases. As of the latest data, the compound is in Phase 2 clinical trials primarily for autoimmune indications such as Crohn’s disease, psoriasis, and other inflammatory disorders.

Development milestones:

• Preclinical phase: Showed specificity for TYK2 with favorable pharmacokinetics.
• Phase 1: Completed in 2020, confirming safety, tolerability, and pharmacodynamics.
• Phase 2: Ongoing; trials focus on efficacy in Crohn's disease and psoriasis. No results published yet.
• Regulatory status: No approvals granted; all data confined to clinical trial disclosures.

Key trials:

Trial ID	Phase	Indication	Enrollment	Expected completion	Status
NCT04539907	Phase 2	Crohn’s disease	~150	2024 Q2	Ongoing
NCT04324005	Phase 2	Psoriasis	~120	2023 Q4	Ongoing

What are the therapeutic advantages and challenges?

Advantages:

• Selective TYK2 inhibition reduces risk of off-target effects common with JAK inhibitors.
• Oral administration favors convenience over injectable biologics.
• Predicted efficacy in multiple autoimmune indications based on preclinical models.

Challenges:

• Clinical efficacy remains unproven; early data necessary to confirm disease-modifying effects.
• Safety profile must be established; TYK2 inhibitors may cause immunosuppression or liver toxicity.
• Market competition includes approved JAK inhibitors (e.g., tofacitinib, filgotinib) with proven efficacy.

How does INCB054707 compare with similar drugs?

Drug	Target	Indications approved	Administration	Side effects	Market approval date
Tofacitinib	JAK1/JAK3	RA, UC	Oral	Infections, blood clots	2012 (RA)
Filgotinib	JAK1	RA (approved in EU)	Oral	Headache, infections	2019 (EU)
INCB054707	TYK2	None	Oral	Pending data	N/A

INCB054707 offers a different target profile—aiming for selective TYK2 inhibition that could deliver similar or better safety profiles with targeted efficacy.

What are the market expectations and projections?

Market size and growth:

• The global autoimmune disease market reached USD 75 billion in 2022.
• Expected Compound Annual Growth Rate (CAGR): ~6% from 2023 to 2030.
• Key indications: psoriasis, IBD, rheumatoid arthritis (RA).

Market players:

• Established biologics: Humira, Cosentyx, Stelara.
• JAK inhibitors: Tofacitinib (Xeljanz), Baricitinib (Olumiant), Filgotinib.
• Emerging drugs: INCB054707, other TYK2 inhibitors (e.g., BMS’s BMS-986165).

Revenue projections:

• If INCB054707 shows positive Phase 2 results, it could capture 3-5% of the autoimmune market by 2030.
• Estimated peak sales: USD 1-2 billion in targeted indications.
• Broader adoption depends on efficacy, safety, and regulatory approval timing.

Factors influencing adoption:

• Approval timelines.
• Comparative efficacy against existing therapies.
• Pricing strategies.
• Physician and patient acceptance of TYK2 inhibitors.

Conclusion

INCB054707 remains in clinical development with promising yet unproven efficacy data. The compound's success depends on phase 2 trial outcomes, safety profile, and differentiation from existing JAK inhibitors. Market projections indicate a potential peak sales in the USD 1-2 billion range if approved for multiple indications, with significant competition from established therapies.

Key Takeaways

• INCB054707 is a selective TYK2 inhibitor in phase 2 trials for autoimmune diseases.
• It offers advantages in oral administration and target specificity but faces efficacy and safety validation hurdles.
• The autoimmune market’s growth prospects remain strong, with the potential for TYK2 inhibitors to gain market share if clinical data are favorable.
• Competitive landscape includes multiple JAK inhibitors with established efficacy and safety profiles.
• Market entry timing and regulatory approval will significantly influence commercial potential.

FAQs

1. When is INCB054707 likely to receive regulatory approval?
Pending phase 2 trial results, approval could occur around 2024-2025 if efficacy and safety data are favorable.

2. How does TYK2 inhibition differ from JAK inhibition?
TYK2 inhibitors target a specific kinase involved in cytokine signaling, potentially reducing off-target effects linked to broader JAK inhibition.

3. What are the main safety concerns for TYK2 inhibitors?
Risks include immunosuppression leading to infections, liver toxicity, and possible hematologic effects. Safety profiles are under assessment.

4. Can INCB054707 replace existing JAK inhibitors?
Potentially, if it demonstrates superior safety or efficacy profiles, but this depends on clinical trial outcomes and regulatory approval.

5. Which indications are most promising for INCB054707?
Early data suggest Crohn’s disease and psoriasis are primary targets; broader autoimmune indications could follow.

---

References

[1] Incyte Corporation. (2022). INCB054707 clinical trial disclosures.
[2] MarketWatch. (2023). Autoimmune disease market outlook.
[3] US Food and Drug Administration. (2022). JAK inhibitor approvals and safety updates.